Definium Therapeutics Inc. shares rally as much as 60% Monday after late-stage trial data showed “groundbreaking” results in the psychedelic drug developer’s experimental treatment for major depressive disorders.
Definium Therapeutics Inc. shares rally as much as 60% Monday after late-stage trial data showed “groundbreaking” results in the psychedelic drug developer’s experimental treatment for major depressive disorders.
<iframe src="https://statesidedaily.com/embed/cluster/61ab0974cfd0d68018f41d4135c2ae46afe23e4c" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Psychedelic Drugmaker Definium Surges on Depression Drug Success"></iframe>
